This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Abramczuk E., Pancer K., Gut W., Litwińska B.: Niepandemiczne koronawirusy człowieka – charakterystyka i diagnostyka. Post. Mikrob. 56, 205–213 (2017)AbramczukE.PancerK.GutW.LitwińskaB.Niepandemiczne koronawirusy człowieka – charakterystyka i diagnostykaPost. Mikrob.562052132017Search in Google Scholar
Ahmed S.F., Quadeer A.A., McKay M.R.: Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses, 12, 254 (2020)AhmedS.F.QuadeerA.A.McKayM.R.Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological StudiesViruses12254202010.3390/v12030254715094732106567Search in Google Scholar
Amanat F., Moran T. i wsp.: A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv, DOI: 10.1101/2020.03.17.20037717 (2020)AmanatF.MoranT.i wsp.A serological assay to detect SARS-CoV-2 seroconversion in humansmedRxivdoi:10.1101/2020.03.17.200377172020Open DOISearch in Google Scholar
AOTiM: Zalecenia w COVID-19, 25.04.2020, http://www.aotm.gov.pl/www/wp-content/uploads/covid_19/2020.04.25_zalecenia%20covid19_v1.1.pdf (7.06.2020)AOTiM: Zalecenia w COVID-19, 25.04.2020http://www.aotm.gov.pl/www/wp-content/uploads/covid_19/2020.04.25_zalecenia%20covid19_v1.1.pdf (7.06.2020)Search in Google Scholar
Bavishi C., Maddox T.M., Messerli F.H.: Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol. DOI: 10.1001/jamacardio.2020.1282 (2020)BavishiC.MaddoxT.M.MesserliF.H.Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System BlockersJAMA Cardiol.DOI:10.1001/jamacardio.2020.1282202032242890Open DOISearch in Google Scholar
Belouzard S., Millet J.K., Licitra B.N., Whittaker G.R.: Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses, 4, 1011–1033 (2012)BelouzardS.MilletJ.K.LicitraB.N.WhittakerG.R.Mechanisms of coronavirus cell entry mediated by the viral spike proteinViruses410111033201210.3390/v4061011339735922816037Search in Google Scholar
Chen L., Xiong J., Bao L., Shi Y.: Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 20, 398–400 (2020)ChenL.XiongJ.BaoL.ShiY.Convalescent plasma as a potential therapy for COVID-19Lancet Infect. Dis.20398400202010.1016/S1473-3099(20)30141-9712821832113510Search in Google Scholar
Chen N., Zhang L. i wsp.: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395, 507–513 (2020)ChenN.ZhangL.i wsp.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive studyLancet395507513202010.1016/S0140-6736(20)30211-7713507632007143Search in Google Scholar
Chen Y., Peng H., Wang L., Zhao Y., Zeng L., Gao H., Liu Y.: Infants Born to Mothers With a New Coronavirus (COVID-19). Front. Pediatr. DOI: 10.3389/fped.2020.00104 (2020)ChenY.PengH.WangL.ZhaoY.ZengL.GaoH.LiuY.Infants Born to Mothers With a New Coronavirus (COVID-19)Front. Pediatr.DOI:10.3389/fped.2020.001042020709845632266184Open DOISearch in Google Scholar
ClinicalTrials.gov: Phase I Clinical Trial of a COVID-19 Vaccine in 18–60 Healthy Adults (CTCOVID-19), 19.05.2020, https://clinicaltrials.gov/ct2/show/NCT04313127 (07.06.2020)ClinicalTrials.govPhase I Clinical Trial of a COVID-19 Vaccine in 18–60 Healthy Adults (CTCOVID-19), 19.05.2020https://clinicaltrials.gov/ct2/show/NCT04313127 (07.06.2020)Search in Google Scholar
Clinical Trials.gov: Use of Ascorbic Acid in Patients With COVID-19, 26.03.2020, https://clinicaltrials.gov/ct2/show/NCT04323514 (08.06.2020)Clinical Trials.govUse of Ascorbic Acid in Patients With COVID-19, 26.03.2020https://clinicaltrials.gov/ct2/show/NCT04323514 (08.06.2020)Search in Google Scholar
Danielsson N., Catchpole M.: Novel coronavirus associated with severe respiratory disease: Case definition and public health measure. Euro Surveill. DOI: 10.2807/ese.17.39.20282-en (2012)DanielssonN.CatchpoleM.Novel coronavirus associated with severe respiratory disease: Case definition and public health measureEuro Surveill.DOI:10.2807/ese.17.39.20282-en201223041021Open DOISearch in Google Scholar
Day M.: COVID-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ, DOI: 10.1136/bmj.m1086 (2020)DayM.COVID-19: ibuprofen should not be used for managing symptoms, say doctors and scientistsBMJdoi:10.1136/bmj.m1086202032184201Open DOISearch in Google Scholar
Du L., He Y., Zhou Y., Liu S., Zheng B. J., Jiang S.: The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226–236 (2009)DuL.HeY.ZhouY.LiuS.Zheng B.J.JiangS.The spike protein of SARS-CoV-a target for vaccine and therapeutic developmentNat. Rev. Microbiol.7226236200910.1038/nrmicro2090275077719198616Search in Google Scholar
Du L., Li F. i wsp.: Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat. Commun. 7, 13473 (2016)DuL.LiF.i wsp.Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccinesNat. Commun.713473201610.1038/ncomms13473512141727874853Search in Google Scholar
Eichler H.G., Cavaleri M., Enzmann H., Scotti F., Sepodes B., Sweeney F., Vamvakas S., Rasi G.: Clinical Trials for Covid-19: Can We Better Use the Short Window of Opportunity? Clin. Pharmacol. Ther. DOI: 10.1002/cpt.1891 (2020)EichlerH.G.CavaleriM.EnzmannH.ScottiF.SepodesB.SweeneyF.VamvakasS.RasiG.Clinical Trials for Covid-19: Can We Better Use the Short Window of Opportunity?Clin. Pharmacol. Ther.DOI:10.1002/cpt.18912020727297532407539Open DOISearch in Google Scholar
Etemad B., Whitcomb D.C.: Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology, 120, 682–707 (2001)EtemadB.WhitcombD.C.Chronic pancreatitis: diagnosis, classification, and new genetic developmentsGastroenterology120682707200110.1053/gast.2001.2258611179244Search in Google Scholar
European Respiratory Society: ACE2 receptor blocers: a novel therapeutic approach for COVID-19, 14.04.2020, https://www.ersnet.org/covid-19-blog/ace2-receptor-blockers-a-novel-the-rapeutic-approach-for-covid-19 (17.05.2020)European Respiratory SocietyACE2 receptor blocers: a novel therapeutic approach for COVID-19, 14.04.2020https://www.ersnet.org/covid-19-blog/ace2-receptor-blockers-a-novel-the-rapeutic-approach-for-covid-19 (17.05.2020)Search in Google Scholar
Fang L., Karakiulakis G., Roth M.: Are Patients With Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection? Lancet Respir. Med. DOI: 10.1016/S2213-2600(20)30116-8 (2020)FangL.KarakiulakisG.RothM.Are Patients With Hypertension and Diabetes Mellitus at Increased Risk for COVID-19 Infection?Lancet Respir. Med.DOI:10.1016/S2213-2600(20)30116-82020711862632171062Open DOISearch in Google Scholar
Forbes: What Do Testicles Have To Do With COVID-19 Coronavirus?, 30.04.2020, https://www.forbes.com/sites/brucelee/2020/04/30/what-do-testicles-have-to-do-with-covid-19-coronavirus/#3c4037691690 (17.05.2020)ForbesWhat Do Testicles Have To Do With COVID-19 Coronavirus?, 30.04.2020https://www.forbes.com/sites/brucelee/2020/04/30/what-do-testicles-have-to-do-with-covid-19-coronavirus/#3c4037691690 (17.05.2020)Search in Google Scholar
Gautret P., Raoult D. i wsp.: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents. DOI: 10.1016/j.ijantimicag.2020.105949 (2020)GautretP.RaoultD.i wsp.Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInt. J. Antimicrob. Agents.DOI:10.1016/j.ijantimicag.2020.1059492020710254932205204Open DOISearch in Google Scholar
GenBank: Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome, 18.03.2020, https://www.ncbi.nlm.nih.gov/nuccore/MN908947.3 (17.05.2020)GenBankSevere acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome, 18.03.2020https://www.ncbi.nlm.nih.gov/nuccore/MN908947.3 (17.05.2020)Search in Google Scholar
Gliński Z., Ciołek J.: Nietoperze rezerwuarami i wektorami wirusów chorobotwórczych dla człowieka i zwierząt. Życie Weterynaryjne, 95, 11–16 (2020)GlińskiZ.CiołekJ.Nietoperze rezerwuarami i wektorami wirusów chorobotwórczych dla człowieka i zwierzątŻycie Weterynaryjne9511162020Search in Google Scholar
Grain J., Flanigan T. i wsp.: Compassionate Use of Remdesivir for Patients with Severe Covid-19. N. Engl. J. Med. 382, 2327–2336 (2020)GrainJ.FlaniganT.i wsp.Compassionate Use of Remdesivir for Patients with Severe Covid-19N. Engl. J. Med.38223272336202010.1056/NEJMoa2007016716947632275812Search in Google Scholar
Guan Y., Poon L.L. i wsp.: Isolation and character ization of viruses related to the SARS coronavirus from animals in southern China. Science, 302, 276–278 (2003)GuanY.PoonL.L.i wsp.Isolation and character ization of viruses related to the SARS coronavirus from animals in southern ChinaScience302276278200310.1126/science.108713912958366Search in Google Scholar
Guan W.J., Zhong N. i wsp.: Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020)GuanW.J.ZhongN.i wsp.Clinical Characteristics of Coronavirus Disease 2019 in ChinaN. Engl. J. Med.38217081720202010.1056/NEJMoa2002032709281932109013Search in Google Scholar
Guangdi L., De Clercq E.: Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discovery. 19, 149–150 (2020)GuangdiL.De ClercqE.Therapeutic options for the 2019 novel coronavirus (2019-nCoV)Nat. Rev. Drug Discovery.19149150202010.1038/d41573-020-00016-032127666Search in Google Scholar
Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y., Yan Y.: The Origin, Transmission and Clinical Therapies on Coronavirus Disease 2019 (COVID-19) Outbreak – An Update on the Status. Mil. Med. Res. DOI: 10.1186/s40779-020-00240-0 (2020)GuoY.R.CaoQ.D.HongZ.S.TanY.Y.ChenS.D.JinH.J.TanK.S.WangD.Y.YanY.The Origin, Transmission and Clinical Therapies on Coronavirus Disease 2019 (COVID-19) Outbreak – An Update on the StatusMil. Med. Res.DOI:10.1186/s40779-020-00240-02020706898432169119Open DOISearch in Google Scholar
Han H.J., Wen H.L., Zhou C.M., Chen F.F., Luo L.M., Liu J.W., Yu X.J.: Bats as reservoirs of severe emerging infectious diseases. Virus Res. 205, 1–6 (2015)HanH.J.WenH.L.ZhouC.M.ChenF.F.LuoL.M.LiuJ.W.YuX.J.Bats as reservoirs of severe emerging infectious diseasesVirus Res.20516201510.1016/j.virusres.2015.05.006713247425997928Search in Google Scholar
Harmer D., Gilbert M., Bormarn R., Clark K.L.: Quantitative mRNA Expression Profiling of ACE 2, a Novel Homologue of Angiotensin Converting Enzyme. FEBS Lett. 532, 107–110 (2002)HarmerD.GilbertM.BormarnR.ClarkK.L.Quantitative mRNA Expression Profiling of ACE 2, a Novel Homologue of Angiotensin Converting EnzymeFEBS Lett.532107110200210.1016/S0014-5793(02)03640-2Search in Google Scholar
Harrison C.: Coronavirus puts drug repurposing on the fast track. Nat. Biotechnol. 38, 379–381 (2020)HarrisonC.Coronavirus puts drug repurposing on the fast trackNat. Biotechnol.38379381202010.1038/d41587-020-00003-132205870Search in Google Scholar
Harvard Health Publishing: Treatments for COVID-19, 24.04. 2020, https://www.health.harvard.edu/diseases-and-conditions/treatments-for-covid-19 (19.05.2020)Harvard Health PublishingTreatments for COVID-19, 24.04. 2020https://www.health.harvard.edu/diseases-and-conditions/treatments-for-covid-19 (19.05.2020)Search in Google Scholar
Hoffmann M., Pöhlmann S. i wsp.: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 181, 271–280 (2020)HoffmannM.PöhlmannS.i wsp.SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell181271280202010.1016/j.cell.2020.02.052710262732142651Search in Google Scholar
Holshue M.L., Pillai S.K. i wsp.: First Case of 2019 Novel Coronavirus in the United States. N. Engl. J. Med. 382, 929–936 (2020)HolshueM.L.PillaiS.K.i wsp.First Case of 2019 Novel Coronavirus in the United StatesN. Engl. J. Med.382929936202010.1056/NEJMoa2001191709280232004427Search in Google Scholar
Horby P.: New data on clinical features, incubation period, and case fatality rate of SARS in Hong Kong and Canada. Euro Surveill. 7, DOI: 10.2807/esw.07.19.02223-en (2003)HorbyP.New data on clinical features, incubation period, and case fatality rate of SARS in Hong Kong and CanadaEuro Surveill.7doi:10.2807/esw.07.19.02223-en2003Open DOISearch in Google Scholar
Huang C., Cao B. i wsp.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395, 497–506 (2020)HuangC.CaoB.i wsp.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaLancet395497506202010.1016/S0140-6736(20)30183-5715929931986264Search in Google Scholar
Imai Y., Penninger J.M. i wsp.: Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 436, 112–116 (2005)ImaiY.PenningerJ.M.i wsp.Angiotensin-converting enzyme 2 protects from severe acute lung failureNature436112116200510.1038/nature03712709499816001071Search in Google Scholar
Kampf G., Todt D., Pfaender S., Steinmann E.: Persistence of coronavirus on inanimate surfaces and their inactivation with biocidal agents, J. Hosp. Infect. 3, 246–251 (2020)KampfG.TodtD.PfaenderS.SteinmannE.Persistence of coronavirus on inanimate surfaces and their inactivation with biocidal agentsJ. Hosp. Infect.3246251202010.1016/j.jhin.2020.01.022713249332035997Search in Google Scholar
Kosobudzki M., Bortkiewicz A.: Genetyczne uwarunkowania chorób układu krążenia. Forum Medycyny Rodzinnej, 6, 1–13 (2012)KosobudzkiM.BortkiewiczA.Genetyczne uwarunkowania chorób układu krążeniaForum Medycyny Rodzinnej61132012Search in Google Scholar
Kuba K., Penninger J.M. i wsp.: A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Medicine, 11, 875–879 (2005)KubaK.PenningerJ.M.i wsp.A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injuryNature Medicine11875879200510.1038/nm1267709578316007097Search in Google Scholar
Lai M.M.C., Holmes K.V.: Coronaviridae and their replication (w) In Fields Virology, red. D.M. Knipe, P.M. Howley, Lippincott Williams & Wilkins, Philadelphia, 2001, s. 1163–1185LaiM.M.C.HolmesK.V.Coronaviridae and their replication (w)InFields Virologyred.KnipeD.M.HowleyP.M.Lippincott Williams & WilkinsPhiladelphia2001s.11631185Search in Google Scholar
Leung J.M., Yang C.X., Tam A., Shaipanich T., Hackett T.L., Singhera G.K., Dorscheid D.R., Sin D.D.: ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19. Eur. Respir. J. DOI: 10.1183/13993003.00688-2020 (2020)LeungJ.M.YangC.X.TamA.ShaipanichT.HackettT.L.SingheraG.K.DorscheidD.R.SinD.D.ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19Eur. Respir. J.DOI:10.1183/13993003.00688-20202020714426332269089Open DOISearch in Google Scholar
Li F.: Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu. Rev. Virol. 3, 237–261 (2016)LiF.Structure, Function, and Evolution of Coronavirus Spike ProteinsAnnu. Rev. Virol.3237261201610.1146/annurev-virology-110615-042301545796227578435Search in Google Scholar
Liu S., Chan T.C., Chu Y.T., Wu J.T.S., Geng X., Zhao N., Cheng W., Chen E., King C.C.: Comparative epidemiology of human infections with Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome Coronaviruses among healthcare personnel. PLoS One, DOI: 10.1371/journal.pone.0149988 (2016)LiuS.ChanT.C.ChuY.T.WuJ.T.S.GengX.ZhaoN.ChengW.ChenE.KingC.C.Comparative epidemiology of human infections with Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome Coronaviruses among healthcare personnelPLoS Onedoi:10.1371/journal.pone.01499882016477307226930074Open DOISearch in Google Scholar
Liu S., Jiang S. i wsp.: Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet, 363, 938–947 (2004)LiuS.JiangS.i wsp.Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitorsLancet363938947200410.1016/S0140-6736(04)15788-7714017315043961Search in Google Scholar
Lokugamage K.G., Narayanan K., Nakagawa K., Terasaki K., Ramirez S.I., Tseng C.K., Makino S.: Middle East Respiratory Syndrome Coronavirus nsp1 inhibits host gene expression by selectively targeting mRNAs transcribed in the nucleus while sparing mRNAs of cytoplasmic origin. J. Virol. 89, 10970–10981 (2015)LokugamageK.G.NarayananK.NakagawaK.TerasakiK.RamirezS.I.TsengC.K.MakinoS.Middle East Respiratory Syndrome Coronavirus nsp1 inhibits host gene expression by selectively targeting mRNAs transcribed in the nucleus while sparing mRNAs of cytoplasmic originJ. Virol.891097010981201510.1128/JVI.01352-15462111126311885Search in Google Scholar
Lu L., Jiang S. i wsp.: Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 5, 3067 (2014)LuL.JiangS.i wsp.Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitorNat. Commun.53067201410.1038/ncomms4067709180524473083Search in Google Scholar
Lui P.Y., Wong L.Y.R., Fung C.L., Siu K.L., Yeung M.L., Yuen K.S., Chan C.P., Woo P.C.Y., Yuen K.Y., Jin D.Y.: Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3. Emerging Microbes Infect. 5, 1–9 (2016)LuiP.Y.WongL.Y.R.FungC.L.SiuK.L.YeungM.L.YuenK.S.ChanC.P.WooP.C.Y.YuenK.Y.JinD.Y.Middle East respiratory syndrome coronavirus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3Emerging Microbes Infect.519201610.1038/emi.2016.33485507427094905Search in Google Scholar
Lundin A., Trybala E. i wsp.: Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virus. PLoS Pathog. DOI: 10.1371/journal.ppat.1004166 (2014)LundinA.TrybalaE.i wsp.Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virusPLoS Pathog.DOI:10.1371/journal.ppat.10041662014403861024874215Open DOISearch in Google Scholar
Ma L., Xie W., Li D., Shi L., Mao Y., Xiong Y., Zhang Y., Zhang M.: Effect of SARS-CoV-2 infection upon male gonadal function: A single center-based study. medRxiv, DOI: 10.1101/2020.03.21.20037267 (2020)MaL.XieW.LiD.ShiL.MaoY.XiongY.ZhangY.ZhangM.Effect of SARS-CoV-2 infection upon male gonadal function: A single center-based studymedRxivdoi:10.1101/2020.03.21.200372672020Open DOISearch in Google Scholar
Mahase E.: Covid-19: what do we know so far about a vaccine? BMJ, DOI: 10.1136/bmj.m1679 (2020)MahaseE.Covid-19: what do we know so far about a vaccine?BMJdoi:10.1136/bmj.m1679202032340998Open DOISearch in Google Scholar
Marczyńska M.: Zalecenia terapeutyczne dla dzieci zakażonych HIV. HIV & AIDS Review, 12, 116–118 (2013)MarczyńskaM.Zalecenia terapeutyczne dla dzieci zakażonych HIVHIV & AIDS Review12116118201310.1016/S1730-1270(13)70003-1Search in Google Scholar
Medicover: Sposoby walki z COVID-19 – leki, osocze rekonwalescencyjne, a może szczepionka?, 19.05.2020, https://www.medicover.pl/o-zdrowiu/sposoby-walki-z-covid-19-lekiosocze-rekonwalescencyjne-a-moze-szczepionka,6916,n,192 (21.05.2020)MedicoverSposoby walki z COVID-19 – leki, osocze rekonwalescencyjne, a może szczepionka?, 19.05.2020https://www.medicover.pl/o-zdrowiu/sposoby-walki-z-covid-19-lekiosocze-rekonwalescencyjne-a-moze-szczepionka,6916,n,192 (21.05.2020)Search in Google Scholar
Międzynarodowa Federacja Farmaceutyczna: COVID-19: Informacje kliniczne i wytyczne dotyczące leczenia, 26.03.2020, https://www.nia.org.pl/wp-content/uploads/2020/04/FIP-Przewodnik-COVID-19-PL-002.pdf (18.05.2020)Międzynarodowa Federacja FarmaceutycznaCOVID-19: Informacje kliniczne i wytyczne dotyczące leczenia, 26.03.2020https://www.nia.org.pl/wp-content/uploads/2020/04/FIP-Przewodnik-COVID-19-PL-002.pdf (18.05.2020)Search in Google Scholar
Mousavizadeh L., Ghasemi S.: Genotype and phenotype of COVID-19: Their roles in pathogenesis. Journal of Microbiology, Immunology and Infection, DOI: 10.1016/j.jmii.2020.03.022 (2020)MousavizadehL.GhasemiS.Genotype and phenotype of COVID-19: Their roles in pathogenesisJournal of Microbiology, Immunology and Infectiondoi:10.1016/j.jmii.2020.03.0222020713818332265180Open DOISearch in Google Scholar
Mrukowicz J., Ściubisz M.: Wyścig po szczepionkę przeciwko SARS-CoV-2. Wielkie nadzieje i wielkie znaki zapytania. Med. Prakt. 5, 36–48 (2020)MrukowiczJ.ŚciubiszM.Wyścig po szczepionkę przeciwko SARS-CoV-2. Wielkie nadzieje i wielkie znaki zapytaniaMed. Prakt.536482020Search in Google Scholar
Nejm Journal Watch: Lack of Efficacy of Hydroxychloroquine or Azithromycin on COVID-19 Clinical Course, https://www.jwatch.org/na51549/2020/05/13/lack-efficacy-hydroxychloroquine-or-azithromycin-covid-19 (07.06.2020)Nejm Journal WatchLack of Efficacy of Hydroxychloroquine or Azithromycin on COVID-19 Clinical Coursehttps://www.jwatch.org/na51549/2020/05/13/lack-efficacy-hydroxychloroquine-or-azithromycin-covid-19 (07.06.2020)Search in Google Scholar
Nextstrain: Phylogeny of SARS-like betacoronaviruses including novel coronavirus from Wuhan using data generated by the Shanghai Public Health Clinical Center & School of Public Health, the National Institute for Viral Disease Control and Prevention, the Institute of Pathogen Biology, and the Wuhan Institute of Virology shared via GISAID, 26.02.2020, https://nextstrain.org/groups/blab/sars-like-cov (17.05.2020)NextstrainPhylogeny of SARS-like betacoronaviruses including novel coronavirus from Wuhan using data generated by the Shanghai Public Health Clinical Center & School of Public Health, the National Institute for Viral Disease Control and Prevention, the Institute of Pathogen Biology, and the Wuhan Institute of Virology shared via GISAID, 26.02.2020https://nextstrain.org/groups/blab/sars-like-cov (17.05.2020)Search in Google Scholar
Puls Medycyny: Leki na koronawirusa SZAR-CoV-2: skuteczne mogą być już znane substancje, 23.03.2020, https://pulsmedycyny.pl/leki-na-koronawirusa-sars-cov-2-skuteczne-moga-bycjuz-znane-substancje-984865 (09.06.2020)Puls MedycynyLeki na koronawirusa SZAR-CoV-2: skuteczne mogą być już znane substancje, 23.03.2020https://pulsmedycyny.pl/leki-na-koronawirusa-sars-cov-2-skuteczne-moga-bycjuz-znane-substancje-984865 (09.06.2020)Search in Google Scholar
Pyrć K.: Ludzkie koronawirusy. Post. Nauk Med. 28, 48–54 (2015)PyrćK.Ludzkie koronawirusyPost. Nauk Med.2848542015Search in Google Scholar
Qin N., Kaijin X. i wsp.: Retrospective study of low-to-moderate dose glucocorticoids on viral clearance in patients with novel coronavirus pneumonia. Chinese Journal of Clinical Infectious Diseases, DOI: 10.3760/cma.j.cn115673-20200225-00072 (2020)QinN.KaijinX.i wsp.Retrospective study of low-to-moderate dose glucocorticoids on viral clearance in patients with novel coronavirus pneumoniaChinese Journal of Clinical Infectious Diseasesdoi:10.3760/cma.j.cn115673-20200225-000722020Open DOISearch in Google Scholar
Rastawicki W., Rokosz-Chudziak N.: Charakterystyka oraz ocena przydatności serologicznych testów w diagnostyce zakażeń wywołanych przez koronawirus SARS-CoV-2 na podstawie dostępnych danych producentów i przeglądu piśmiennictwa. Przegl. Epidemiol. 74, 113–132 (2020)RastawickiW.Rokosz-ChudziakN.Charakterystyka oraz ocena przydatności serologicznych testów w diagnostyce zakażeń wywołanych przez koronawirus SARS-CoV-2 na podstawie dostępnych danych producentów i przeglądu piśmiennictwaPrzegl. Epidemiol.741131322020Search in Google Scholar
Reuters: Poland reports first coronavirus case – health minister, 4.03.2020, https://www.reuters.com/article/us-health-coronavirus-poland/poland-reports-first-coronavirus-case-health-minister-idUSKBN20R0U7 (05.06.2020)ReutersPoland reports first coronavirus case – health minister, 4.03.2020https://www.reuters.com/article/us-health-coronavirus-poland/poland-reports-first-coronavirus-case-health-minister-idUSKBN20R0U7 (05.06.2020)Search in Google Scholar
Rut W., Groborz K., Zhang L., Sun X., Zmudzinski M., Hilgenfeld R., Drag M.: Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti-COVID-19 drug design. bioRxiv, DOI: 10.1101/2020.03.07.981928 (2020)RutW.GroborzK.ZhangL.SunX.ZmudzinskiM.HilgenfeldR.DragM.Substrate specificity profiling of SARS-CoV-2 Mpro protease provides basis for anti-COVID-19 drug designbioRxivdoi:10.1101/2020.03.07.9819282020Open DOISearch in Google Scholar
Sama I.E., Voors A.A. i wsp.: Circulating Plasma Concentrations of Angiotensin-Converting Enzyme 2 in Men and Women With Heart Failure and Effects of Renin-Angiotensin-Aldosterone Inhibitors. Eur. Heart J. 41, 1810–1817 (2020)SamaI.E.VoorsA.A.i wsp.Circulating Plasma Concentrations of Angiotensin-Converting Enzyme 2 in Men and Women With Heart Failure and Effects of Renin-Angiotensin-Aldosterone InhibitorsEur. Heart J.4118101817202010.1093/eurheartj/ehaa373723919532388565Search in Google Scholar
Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B.: Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). A Review. JAMA, 323, 1824–1836 (2020)SandersJ.M.MonogueM.L.JodlowskiT.Z.CutrellJ.B.Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19). A ReviewJAMA323182418362020Search in Google Scholar
Sheahan T.P., Baric R.S. i wsp.: Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci. Transl. Med. DOI: 10.1126/scitranslmed.aal3653 (2017)SheahanT.P.BaricR.S.i wsp.Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronavirusesSci. Transl. Med.DOI:10.1126/scitranslmed.aal36532017556781728659436Open DOISearch in Google Scholar
Sheahan T.P., Baric R.S. i wsp.: Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. DOI: 10.1038/s41467-019-13940-6SheahanT.P.BaricR.S.i wsp.Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoVNat. Commun.DOI:10.1038/s41467-019-13940-6695430231924756Open DOISearch in Google Scholar
Soro-Paavonen A., Gordin D., Forsblom C., Rosengard-Barlund M., Waden J., Thorn L., Sandholm N., Thomas M.C., Groop P.H., FinnDiane Study Group.: Circulating ACE2 Activity Is Increased in Patients With Type 1 Diabetes and Vascular Complications. J. Hypertens. 30, 375–383 (2012)Soro-PaavonenA.GordinD.ForsblomC.Rosengard-BarlundM.WadenJ.ThornL.SandholmN.ThomasM.C.GroopP.H.FinnDianeStudy Group.Circulating ACE2 Activity Is Increased in Patients With Type 1 Diabetes and Vascular ComplicationsJ. Hypertens.30375383201210.1097/HJH.0b013e32834f04b622179088Search in Google Scholar
Stilhano R.S., Costa A.J., Nishino M.A., Shams S., Bartolomeo C.S., Breithaupt-Faloppa A.C., Silva E.A., Ramirez A.L., Prado C.M., Ureshino R.P.: SARS-CoV-2 and the Possible Connection to ERs, ACE2 and RAGE: Focus on Susceptibility Factors. Preprints, DOI: 10.20944/preprints202005.0178.v1 (2020)StilhanoR.S.CostaA.J.NishinoM.A.ShamsS.BartolomeoC.S.Breithaupt-FaloppaA.C.SilvaE.A.RamirezA.L.PradoC.M.UreshinoR.P.SARS-CoV-2 and the Possible Connection to ERs, ACE2 and RAGE: Focus on Susceptibility FactorsPreprintsdoi:10.20944/preprints202005.0178.v12020Open DOISearch in Google Scholar
Tang X., Lu J. i wsp.: On the orgin and continuing evolution of SARS-CoV-2. Natl. Sci. Rev. 7, 1012–1023 (2020)TangX.LuJ.i wsp.On the orgin and continuing evolution of SARS-CoV-2Natl. Sci. Rev.710121023202010.1093/nsr/nwaa036710787534676127Search in Google Scholar
Tu C., Wang L.F. i wsp.: Antibodies to SARS coro navirus in civets. Emerging Infect. Dis. 10, 2244–2248 (2004)TuC.WangL.F.i wsp.Antibodies to SARS coro navirus in civetsEmerging Infect. Dis.1022442248200410.3201/eid1012.040520332339915663874Search in Google Scholar
Vabret A., Dina J., Brison E., Brouard J., Freymuth F.: Human coronaviruses. Pathol. Biol. (Paris) 57, 149–160 (2009)VabretA.DinaJ.BrisonE.BrouardJ.FreymuthF.Human coronavirusesPathol. Biol.Paris57149160200910.1016/j.patbio.2008.02.018712562018456429Search in Google Scholar
van der Hoek L., Pyrć K., Berkhout B.: Human coronavirus NL63, a new respiratory virus. FEMS Microbiol. Rev. 30, 760–773 (2006)van der HoekL.PyrćK.BerkhoutB.Human coronavirus NL63, a new respiratory virusFEMS Microbiol. Rev.30760773200610.1111/j.1574-6976.2006.00032.x710977716911043Search in Google Scholar
van Doremalen N., Munster V.J. i wsp.: Aerosol and Surface Stability of SARS-CoV-2 as Compared With SARS-Cov-1. N. Engl. J. Med. 382, 1564–1567 (2020)van DoremalenN.MunsterV.J.i wsp.Aerosol and Surface Stability of SARS-CoV-2 as Compared With SARS-Cov-1N. Engl. J. Med.38215641567202010.1056/NEJMc2004973712165832182409Search in Google Scholar
Vashist S.K.: In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. Diagnostics, DOI: 10.3390/disgnostics10040202 (2020)VashistS.K.In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging TrendsDiagnosticsdoi:10.3390/disgnostics100402022020Open DOISearch in Google Scholar
Vijaykrishna D., Smith G.J.D., Zhang J.X., Peiris J.S.M., Chen H., Guan Y.: Evolutionary insights into the ecology of coronaviruses. J. Virol. 81, 4012–4020 (2007)VijaykrishnaD.SmithG.J.D.ZhangJ.X.PeirisJ.S.M.ChenH.GuanY.Evolutionary insights into the ecology of coronavirusesJ. Virol.8140124020200710.1128/JVI.02605-06186612417267506Search in Google Scholar
Villar J., Gonzales-Martin J.M. i wsp.: Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir. Med. 8, 267–276 (2020)VillarJ.Gonzales-MartinJ.M.i wsp.Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trialLancet Respir. Med.8267276202010.1016/S2213-2600(19)30417-532043986Search in Google Scholar
Waliszewski K., Słomski R., Jura J., Oszkinis G., Gabriel M., Strauss E., Pawlak A.: Zmiany częstości alleli i rozkładu genotypów genu ACE w populacji chorych na tętniaka aorty brzusznej. J. Med. Sci. 12, 169–175 (2003)WaliszewskiK.SłomskiR.JuraJ.OszkinisG.GabrielM.StraussE.PawlakA.Zmiany częstości alleli i rozkładu genotypów genu ACE w populacji chorych na tętniaka aorty brzusznejJ. Med. Sci.121691752003Search in Google Scholar
Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M., Shi Z., Hu Z., Zhong W., Xiao G.: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30, 269–271 (2020)WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30269271202010.1038/s41422-020-0282-0705440832020029Search in Google Scholar
Wang N., Shang J., Jiang S., Du L.: Subunit Vaccines Against Emering Pathogenic Human Coronaviruses. Front. Mikrobiol. DOI: 10.3389/fmicb.2020.00298 (2020)WangN.ShangJ.JiangS.DuL.Subunit Vaccines Against Emering Pathogenic Human CoronavirusesFront. Mikrobiol.DOI:10.3389/fmicb.2020.002982020710588132265848Open DOISearch in Google Scholar
Wang Q., Wong G., Lu G., Yan J., Gao G.F.L.: MERS-CoV spike protein: targets for vaccines and therapeutics. Antiviral Res. 133, 165–177 (2016)WangQ.WongG.LuG.YanJ.GaoG.F.L.MERS-CoV spike protein: targets for vaccines and therapeuticsAntiviral Res.133165177201610.1016/j.antiviral.2016.07.015711376527468951Search in Google Scholar
World Health Organization: Coronavirus diseae (COVID-19) Pandemic, https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (16.05.2020)World Health OrganizationCoronavirus diseae (COVID-19) Pandemichttps://www.who.int/emergencies/diseases/novel-coronavirus-2019 (16.05.2020)Search in Google Scholar
World Health Organization: Director-General’s opening remarks at the media briefing on COVID-19, 11.03.2020, https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19--11-march-2020 (16.05.2020)World Health OrganizationDirector-General’s opening remarks at the media briefing on COVID-19, 11.03.2020https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19--11-march-2020 (16.05.2020)Search in Google Scholar
World Health Organization: Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases, 2.03.2020, https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-laboratory-2020.4-eng.pdf?sequence=1&i-sAllowed=y, (17.05.2020)World Health OrganizationLaboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases, 2.03.2020https://apps.who.int/iris/bitstream/handle/10665/331329/WHO-COVID-19-laboratory-2020.4-eng.pdf?sequence=1&i-sAllowed=y, (17.05.2020)Search in Google Scholar
World Health Organization: Middle East respiratory syndrome coronavirus (MERS-CoV). Summary of current situation, literature update and risk assessment. 07.07.2015, http://apps.who.int/iris/bitstream/10665/179184/2/WHO_MERS_RA_15.1_eng.pdf (16.05.2020)World Health OrganizationMiddle East respiratory syndrome coronavirus (MERS-CoV). Summary of current situation, literature update and risk assessment. 07.07.2015http://apps.who.int/iris/bitstream/10665/179184/2/WHO_MERS_RA_15.1_eng.pdf (16.05.2020)Search in Google Scholar
World Health Organization: Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003, 31.12.2003, https://www.who.int/csr/sars/country/table2004_04_21/en// (16.05.2020)World Health OrganizationSummary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003, 31.12.2003https://www.who.int/csr/sars/country/table2004_04_21/en// (16.05.2020)Search in Google Scholar
Worldometer: COVID-19 Coronavirus pandemic, 19.05.2020, https://www.worldometers.info/coronavirus (20.05.2020)WorldometerCOVID-19 Coronavirus pandemic, 19.05.2020https://www.worldometers.info/coronavirus (20.05.2020)Search in Google Scholar
Wu D., Yang X.O.: TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J. Microbiol. Immunol. Infect. 53, 368–370 (2020)WuD.YangX.O.TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor FedratinibJ. Microbiol. Immunol. Infect.53368370202010.1016/j.jmii.2020.03.005715621132205092Search in Google Scholar
Wysocki J., Gonzales-Pacheco F.R., Battle D.: Angiotensin-converting enzyme 2: Possible role in hypertension and kidney disease. Current Hypertension Reports, 10, 70–77 (2008)WysockiJ.Gonzales-PachecoF.R.BattleD.Angiotensin-converting enzyme 2: Possible role in hypertension and kidney diseaseCurrent Hypertension Reports107077200810.1007/s11906-008-0014-1708941018367030Search in Google Scholar
Xiao F., Hiremath S., Knoll G., Zimpelmann J., Srivaratharajah K., Jadhav D., Fergusson D., Kennedy C.R., Burns K.D.: Increased urinary angiotensin-converting enzyme 2 in renal transplant patients with diabetes. PLoS One, DOI: 10.1371/journal.pone.0037649 (2012)XiaoF.HiremathS.KnollG.ZimpelmannJ.SrivaratharajahK.JadhavD.FergussonD.KennedyC.R.BurnsK.D.Increased urinary angiotensin-converting enzyme 2 in renal transplant patients with diabetesPLoS Onedoi:10.1371/journal.pone.00376492012335829222629438Open DOISearch in Google Scholar
Xiao F., Tang M., Zheng X., Liu Y., Li X., Shan H.: Evidence for gastrointensinal infection of SARS-CoV-2. Gastroenterology, 158, 1831–1833 (2020)XiaoF.TangM.ZhengX.LiuY.LiX.ShanH.Evidence for gastrointensinal infection of SARS-CoV-2Gastroenterology15818311833202010.1053/j.gastro.2020.02.055713018132142773Search in Google Scholar
Xinhuanet: New-type coronavirus causes pneumonia in Wuhan: expert, 09.01.2020, http://www.xinhuanet.com/english/2020-01/09/c_138690570.htm (16.05.2020)XinhuanetNew-type coronavirus causes pneumonia in Wuhan: expert, 09.01.2020http://www.xinhuanet.com/english/2020-01/09/c_138690570.htm (16.05.2020)Search in Google Scholar
Zhang H., Li H.B., Lyu J.R., Lei X.M., Li W., Wu G., Lyu J., Dai Z.M.: Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int. J. Infect. Dis. 96, 19–24 (2020)ZhangH.LiH.B.LyuJ.R.LeiX.M.LiW.WuG.LyuJ.DaiZ.M.Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infectionInt. J. Infect. Dis.961924202010.1016/j.ijid.2020.04.027716507932311451Search in Google Scholar
Zhou P., Shi Z.L. i wsp.: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579, 270–273 (2020)ZhouP.ShiZ.L.i wsp.A pneumonia outbreak associated with a new coronavirus of probable bat originNature579270273202010.1038/s41586-020-2012-7709541832015507Search in Google Scholar
Zhu N., Tan W. i wsp.: A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020)ZhuN.TanW.i wsp.A novel coronavirus from patients with pneumonia in China, 2019N. Engl. J. Med.382727733202010.1056/NEJMoa2001017709280331978945Search in Google Scholar
